NanoString Technologies (NASDAQ: NSTG) and Biocept (NASDAQ:BIOC) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, dividends, institutional ownership, analyst recommendations and profitability.
This is a breakdown of current ratings and recommmendations for NanoString Technologies and Biocept, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
NanoString Technologies presently has a consensus target price of $20.00, indicating a potential upside of 42.15%. Biocept has a consensus target price of $2.50, indicating a potential upside of 100.00%. Given Biocept’s stronger consensus rating and higher probable upside, analysts clearly believe Biocept is more favorable than NanoString Technologies.
Earnings and Valuation
This table compares NanoString Technologies and Biocept’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|NanoString Technologies||$101.82 million||3.00||-$35.97 million||($2.13)||-6.61|
|Biocept||$4.68 million||7.10||-$17.28 million||($1.26)||-0.99|
Biocept has higher revenue, but lower earnings than NanoString Technologies. NanoString Technologies is trading at a lower price-to-earnings ratio than Biocept, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
89.5% of NanoString Technologies shares are owned by institutional investors. Comparatively, 15.3% of Biocept shares are owned by institutional investors. 24.4% of NanoString Technologies shares are owned by insiders. Comparatively, 7.7% of Biocept shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
This table compares NanoString Technologies and Biocept’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility & Risk
NanoString Technologies has a beta of 1.07, suggesting that its share price is 7% more volatile than the S&P 500. Comparatively, Biocept has a beta of 3.01, suggesting that its share price is 201% more volatile than the S&P 500.
Biocept beats NanoString Technologies on 7 of the 13 factors compared between the two stocks.
About NanoString Technologies
NanoString Technologies, Inc. develops, manufactures and sells intuitive products that unlock scientifically valuable and clinically actionable biologic information from minute amounts of tissue. The Company is engaged in the development, manufacture and commercialization of instruments, consumables and services for profiling the activity of hundreds of genes and proteins simultaneously from a single tissue sample. The Company’s nCounter Analysis System is an automated, multi-application, digital detection and counting system, which directly profiles hundreds of molecules simultaneously using a barcoding technology. The Company markets systems and related consumables to researchers in academic, government and biopharmaceutical laboratories for use in understanding fundamental biology and the molecular basis of diseases, such as cancer, and to clinical laboratories and medical centers for diagnostic use.
Biocept, Inc. is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company’s Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample. The ctDNA technology enables mutation detection and is applicable to nucleic acid from CTCs or other sample types, such as blood plasma. The Company commercializes its Target-Selector assays for a range of solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), gastric cancer, colorectal cancer, prostate cancer and melanoma.
What are top analysts saying about NanoString Technologies Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for NanoString Technologies Inc. and related companies.